Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism

Journal of Neurochemistry

Volumn 85, Issue 4, 2003, Pages 1018-1025

  Maccarrone, Mauro ^a,b   Gubellini, Paolo ^a,c   Bari, Monica ^a   Picconi, Barbara ^a,d   Battista, Natalia ^a   Centonze, Diego ^a,d   Bernardi, Giorgio ^a,d   Finazzi Agrò, Alessandro ^a   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c CNRS   (France)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Anandamide; CB1 receptor; Dopamine; Glutamate; Levodopa; Striatum

Indexed keywords

ANANDAMIDE; BENSERAZIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CARRIER PROTEIN; DOPAMINE; FATTY ACID AMIDASE; HYDROLASE; LEVODOPA; OXIDOPAMINE;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; ELECTROPHYSIOLOGY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STRIATE CORTEX;

ANIMALIA; PARKINSONIA;

EID: 0038249025     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01759.x     Document Type: Article

References (35)

1. Ameri A. (1999) The effects of cannabinoids on the brain. Prog. Neurobiol. 58, 315-348.
2. 2 receptor responses by anandamide transport inhibitor. J. Neurosci. 20, 3401-3407.
3. Berke J. D. and Hyman S. E. (2000) Addiction, dopamine and the molecular mechanisms of memory. Neuron 25, 515-532.
4. Brotchie J. M. (2000) The neural mechanisms underlying levodopainduced dyskinesia in Parkinson's disease. Ann. Neurol. 47, S105-S112.
5. Calabresi P., Mercuri N. B., Sancesario G. and Bernardi G. (1993) Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116, 433-452.
6. Calabresi P., Centonze D. and Bernardi G. (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23, S57-S63.
7. Centonze D., Picconi B., Gubellini P., Bernardi G. and Calabresi P. (2001) Dopaminergic control of synaptic plasticity in the striatum. Eur. J. Neurosci. 13, 1071-1077.
8. 2 dopamine receptor-deficient mice. J. Neurophysiol. 85, 659-670.
9. Chase T. N. and Oh J. D. (2000) Striatal dopamine- and glutamatemediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91.
10. Cravatt B. F., Demarest K., Patricelli M. P., Bracey M. H., Giang D. K., Martin B. R. and Lichtman A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371-9376.
11. De Petrocellis L., Bisogno T., Maccarrone M., Davis J. B., Finazzi-Agrò A. and Di Marzo V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12856-12863.
12. Fox S. H., Henry B., Hill M., Crossman A. and Brotchie J. (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Dis. 17, 1180-1187.
13. Gerdeman G. and Lovinger D. M. (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85, 468-471.
14. Giuffrida A. and Piomelli D. (2000) The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem. Phys. Lipids 108, 151-158.
15. Giuffrida A., Parsons L. H., Kerr T. M., Rodriguez de Fonseca F., Navarro M. and Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-362.
16. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A. and Maccarrone M. (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22, 6900-6907.
17. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1991) Characterization and localization of cannabinoid receptor in the brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
18. Hillard C. J. and Jarrahian A. (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids 108, 123-134.
19. Howlett A. C. and Mukhopadhyay S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53-70.
20. Huang C.-C., Lo S.-W. and Hsu K.-S. (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 523, 731-748.
21. Jiang Z. G. and North R. A. (1991) Membrane properties and synaptic responses of rat striatal neurones in vitro. J. Physiol. 443, 533-553.
22. Kita T., Kita H. and Kitai S. T. (1984) Passive electrical membrane properties of rat neostriatal neurons in an in vitro slice preparation. Brain Res. 300, 129-139.
23. Maccarrone M., van der Stelt M., Rossi A., Veldink G. A., Vliegenthart J. F. G. and Finazzi-Agrò A. (1998) Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273, 32332-32339.
24. Maccarrone M., Attinà M., Bari M., Cartoni A., Ledent C. and FinazziAgrò A. (2001a) Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J. Neurochem. 78, 339-348.
25. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C. and Finazzi-Agrò A. (2001b) Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J. Immunol. 166, 7183-7189.
26. 1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40, 918-926.
27. 31P NMR and enzyme activity study. J. Lipid Res. 41, 985-990.
28. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, London.
29. Pertwee R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther 74, 129-180.
30. Picconi B., Pisani A., Centonze D., Battaglia G., Storto M., Nicoletti F., Bernardi G. and Calabresi P. (2002) Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa-treatment. Brain 125, 1-11.
31. Schmid P. C., Krebsbach R. J., Perry S. R., Dettmer T. M., Maasson J. L. and Schmid H. H. (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375, 117-120.
32. Schwartig R. K. W. and Huston J. P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Prog. Neurobiol. 50, 275-331.
33. Sieradzan K. A., Fox S. H., Hill M., Dick J. P., Crossman A. R. and Brotchie J. M. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108-2111.
34. Tang K.-C., Low M. J., Grandy D. K. and Lovinger D. M. (2001) Dopamine-dependent synaptic plasficity in striatum dunng in vivo development. Proc. Natl Acad. Sci. USA 98, 1255-1260.
35. Ungerstet U. and Arbuthnott G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal pathway. Brain Res. 24, 485-493.